chromosomal-instability-agent

name	chromosomal-instability-agent
description	AI-powered analysis of chromosomal instability (CIN) signatures for cancer prognosis, immunotherapy response prediction, and therapeutic vulnerability identification.

Chromosomal Instability Agent

The Chromosomal Instability Agent analyzes CIN signatures to predict cancer prognosis, immunotherapy response, and therapeutic vulnerabilities. It integrates copy number alterations, aneuploidy scores, and CIN-related gene expression for comprehensive genomic instability assessment.

When to Use This Skill

• When assessing tumor aneuploidy and chromosomal instability levels.
• To predict prognosis based on CIN signatures.
• For identifying tumors vulnerable to CIN-targeted therapies (PARP, ATR, WEE1).
• When analyzing immune evasion mechanisms related to CIN.
• To stratify patients for immunotherapy based on CIN status.

Core Capabilities

1. CIN Scoring: Calculate comprehensive CIN scores from copy number data.

2. Aneuploidy Quantification: Measure arm-level and focal copy number alterations.

3. CIN Gene Expression: Analyze CIN70 and other transcriptional signatures.

4. Immune Correlation: Assess CIN-immune microenvironment relationships.

5. Therapeutic Vulnerability: Identify CIN-targeted treatment options.

6. Prognostic Modeling: Predict outcomes based on CIN signatures.

CIN Metrics

Metric	Calculation	Interpretation
Aneuploidy score	Arm-level alterations	Chromosome-level CIN
SCNA burden	Total CNV alterations	Overall instability
Weighted GII	Fraction altered genome	Focal vs broad changes
CIN70	70-gene signature	Transcriptional CIN
WGII	Weighted genome instability	Comprehensive score

CIN70 Signature Genes

Core genes reflecting CIN phenotype:

• Mitotic checkpoint: BUB1, BUBR1, MAD2L1
• Kinetochore: CENPA, CENPF, NDC80
• DNA replication: MCM2-7, ORC1
• Cell cycle: CCNB1, CCNB2, CDK1, PLK1
• Chromosome segregation: AURKB, KIF2C, KIF11

Workflow

1. Input: Copy number data (segments), gene expression, mutation data.

2. CNV Analysis: Calculate arm-level and focal alterations.

3. Signature Scoring: Compute CIN70 and other transcriptional signatures.

4. Integration: Combine DNA and RNA-based CIN metrics.

5. Immune Analysis: Correlate CIN with TME composition.

6. Vulnerability Assessment: Identify targetable dependencies.

7. Output: CIN scores, prognosis, treatment recommendations.

Example Usage

User: "Analyze chromosomal instability in this breast cancer sample and identify treatment vulnerabilities."

Agent Action:

python3 Skills/Oncology/Chromosomal_Instability_Agent/cin_analyzer.py \
    --cnv_segments tumor_cnv.tsv \
    --expression rnaseq_tpm.tsv \
    --mutations somatic.maf \
    --tumor_type breast_cancer \
    --signatures cin70,cin25 \
    --output cin_report/

CIN and Immune Evasion

High CIN Associates With:

• Reduced immune infiltration
• Lower checkpoint inhibitor response
• Increased immune evasion
• cGAS-STING activation (paradoxical)

Mechanisms:

1. Loss of tumor suppressors on chromosome arms
2. Chronic inflammatory signaling
3. Aneuploidy-induced stress responses
4. Subclonal diversification

Therapeutic Vulnerabilities

Target	Agents	CIN Context
PARP	Olaparib, etc.	High CIN + HRD
ATR	Berzosertib	Replication stress
WEE1	Adavosertib	G2/M dependency
CHK1	Prexasertib	Cell cycle checkpoint
KIF11	Ispinesib	Mitotic dependency
Aurora kinases	Alisertib	Mitotic errors

CIN-Based Patient Stratification

CIN Level	Prognosis	ICI Response	Alternative Therapy
Low	Better	Better	Standard care
Intermediate	Variable	Variable	Combination therapy
High	Poor	Poor	CIN-targeted agents
Extreme	Very poor	Immune desert	Chemotherapy

AI/ML Components

CIN Score Prediction:

• Random forest on CNV features
• Expression-based CIN inference
• Multi-modal integration

Prognosis Modeling:

• Cox regression with CIN features
• Cancer-type specific models
• Integration with clinical variables

Therapeutic Matching:

• GDSC/CCLE drug sensitivity
• CIN-drug response correlations
• Combination predictions

Pan-Cancer CIN Patterns

Cancer Type	Typical CIN Level	Driver Events
Ovarian HGSOC	Very high	TP53, BRCA
Triple-neg breast	High	TP53, PI3K
Colorectal MSS	Moderate-high	APC, TP53
Colorectal MSI	Low	MMR deficiency
Thyroid (PTC)	Low	BRAF, RAS
Melanoma	Moderate	BRAF, NRAS

Prerequisites

• Python 3.10+
• GISTIC2 or similar for CNV analysis
• Gene signature databases
• Survival analysis packages

Related Skills

• HRD_Analysis_Agent - For HR-specific instability
• Pan_Cancer_MultiOmics_Agent - For pan-cancer context
• Tumor_Clonal_Evolution_Agent - For evolutionary dynamics

Research Applications

1. Biomarker Development: CIN as predictive marker
2. Drug Development: CIN-targeted therapy trials
3. Evolution Studies: Track CIN changes over time
4. Resistance Mechanisms: CIN and drug resistance

Author

AI Group - Biomedical AI Platform